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Pneumocystis jirovecii pneumonia (PCP) is associated with high mortality in immunocompromised patients without human
immunodeficiency virus infection. However, chemoprophylaxis is highly effective. In patients with solid tumours or haematologic
malignancy, several risk factors for developing PCP have been identified, predominantly corticosteroid therapy. The aims of this study
were to identify the potentially preventable cases of PCP in patients receiving corticosteroid therapy at a tertiary care cancer centre
and to estimate the frequency of utilisation of chemoprophylaxis in these patients. Two retrospective reviews were performed. Over
a 10-year period, 14 cases of PCP were identified: no cases were attributable to failed chemoprophylaxis, drug allergy or intolerance.
During a 6-month period, 73 patients received high-dose corticosteroid therapy (X25mg prednisolone or X4mg dexamethasone
daily) for X4 weeks. Of these, 22 (30%) had haematologic malignancy, and 51 (70%) had solid tumours. Fewer patients with solid
tumours received prophylaxis compared to patients with haematologic malignancy (3.9 vs 63.6%, Po0.0001). Guidelines for PCP
chemoprophylaxis in patients with haematologic malignancy or solid tumours who receive corticosteroid therapy are proposed.
Successful primary prevention of PCP in this population will require a multifaceted approach targeting the suboptimal prescribing
patterns for chemoprophylaxis.
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Pneumocystis jirovecii pneumonia (PCP) is a potentially life-
threatening opportunistic infection seen predominantly in im-
munosuppressed individuals, and with increasing frequency in
human immunodeficiency (HIV)-negative patients. The case
fatality rate among HIV-negative patients with PCP has remained
approximately 50% over the last three decades (Walzer et al, 1974;
Sepkowitz et al, 1992; Sepkowitz, 2002), despite identification of
risk factors, including malignancy (Sepkowitz et al, 1992; Zahar
et al, 2002), haematologic disorders (Sepkowitz et al, 1992),
radiation therapy (Mathew and Grossman, 2003), chemotherapy
(Hughes et al, 1975; Sepkowitz et al, 1992), organ transplantation
(Hardy et al, 1984; Sepkowitz et al, 1995) and CD4
þ lymphopenia
(Mansharamani et al, 2000). In patients with solid tumours or
haematologic malignancy, corticosteroid therapy is the most
common predisposing risk factor for developing PCP (Sepkowitz
et al, 1992; Sepkowitz, 1993; Yale and Limper, 1996).
Identifying patients who are at risk of PCP is important, as
highly effective prophylactic strategies are available. Risk assess-
ment based on intensity of corticosteroid therapy is possible as
dose, duration and tapering of corticosteroid therapy appear to
impact upon the risk for development of PCP (Sepkowitz et al,
1992; Slivka et al, 1993; Sepkowitz, 1996; Yale and Limper, 1996).
In a study of 116 HIV-negative patients with PCP, the median daily
dose of corticosteroid was equivalent to 30mg prednisolone, and
the median duration of therapy before the onset of infection was 12
weeks (Yale and Limper, 1996). Sepkowitz et al have recommended
that any patient with an underlying immunologic disorder
(including malignancy) who receives the equivalent of at least
20mg of prednisolone daily for more than 1 month be given
prophylaxis (Sepkowitz et al, 1995; Sepkowitz, 1996).
The Peter MacCallum Cancer Centre (PMCC) is a tertiary care
cancer centre which sees the full spectrum of malignant disorders.
Since 1999, guidelines for trimethoprim–sulphamethoxazole
(TMP–SMX) prophylaxis have been utilised in patients receiving
selected high-intensity chemotherapy protocols: hyper-CVAD
(Kantarjian et al, 2000), VAD (Barlogie et al, 1984), CEVAD (Giles
et al, 2000) and FLAG (Estey et al, 1994). Adherence to the
guidelines and frequency of chemoprophylaxis in other patients
with haematological malignancy or solid tumours is unknown.
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sThe aims of this study were to (1) identify the potentially
preventable cases of PCP, and (2) estimate the proportional use of
suitable chemoprophylaxis in patients at risk for PCP on the basis
of corticosteroid therapy. Finally, we propose a strategy for PCP
prophylaxis in patients with haematological malignancy or solid
tumours, who receive high-dose corticosteroid therapy.
MATERIALS AND METHODS
To study the relationship between use of prophylaxis and
development of PCP, a retrospective case series of all confirmed
cases of PCP treated at PMCC between 1994 and 2003 was
performed. The proportion of at-risk patients receiving prophy-
laxis was estimated by a retrospective review of hospital pharmacy
records, identifying the use of prophylaxis in patients receiving
corticosteroid therapy during a 6-month period (2003).
Pneumocystis jirovecii pneumonia cases
All patients with a discharge diagnosis of PCP from 1/1/1994 to 31/
12/2003 were identified by ICD9-CM or ICD10-AM code. A case
was defined as a patient with morphologic evidence of Pneumo-
cystis by toluidine blue staining and/or direct fluorescent antigen
detection in a respiratory specimen (sputum, induced sputum or
bronchoscopy specimen). Corticosteroid therapy was defined as
administration of prednisolone, dexamethasone, hydrocortisone
or methylprednisolone in addition to any chemotherapeutic
regimen containing dexamethasone or prednisolone components.
Only cases receiving corticosteroid therapy prior to onset of PCP
were studied.
Charts were reviewed, and demographic details, clinical find-
ings, predisposing factors and treatment outcome established for
each case. Dose of corticosteroid, duration of therapy prior to
onset of symptoms and tapering of doses were determined. Other
possible risk factors for PCP were analysed: radiation therapy,
chemotherapy and stem cell transplantation. Use of prophylaxis
(TMP–SMX, dapsone, pentamidine), and potential reasons for
lack of prophylaxis (previous drug allergy or intolerance, patient
not considered high risk by treating physician, patient requiring
palliative care services, noncompliance) were documented.
Prophylaxis in at-risk patients
Pharmacy records for a 6-month period (1/6/03–30/11/03) were
used to identify patients at PMCC who were at risk for
development of PCP on the basis of steroid therapy and underlying
malignancy. At-risk cases were defined as patients who were
dispensed with X25mg prednisolone or X4mg dexamethasone
daily for X4 weeks. Chart review was performed to determine the
demographic details and to identify concurrent use of PCP
prophylaxis (as defined above).
Statistical analysis
Statistical comparison of patients with haematologic malignancy
and solid tumours was carried out by the w
2-test, with Po0.05
deemed significant.
RESULTS
Pneumocystis jirovecii pneumonia cases
Out of 60 patients identified with a discharge diagnosis of PCP, 35
were excluded because no microbiological confirmation of PCP
was made. Of the remaining 25 patients with confirmed PCP, 11
had no corticosteroid therapy administered prior to onset of PCP.
Two of these had solid tumours (colorectal adenocarcinoma,
anaplastic thyroid carcinoma) and nine patients had haematolo-
gical malignancy (AML (three), non-Hodgkin’s lymphoma (two),
Hodgkin’s disease (two), CLL (two)). In the subgroup with
haematological malignancy, a number of predisposing factors
were identified: external beam radiation (three), autologous stem
cell transplantation (two), and chemotherapy with fludarabine
(four), cyclophosphamide (three), cytarabine (three) and metho-
trexate (one). P. jirovecii pneumonia was the cause of death in
three out of 11 cases.
Of the 14 patients who received steroid therapy prior to onset of
microbiologically confirmed PCP, incomplete data were available
for one patient (steroid therapy commenced prior to transfer from
another institution). This patient was not included in analysis.
Among the 13 analysed cases, the mean age was 56 years (eight
males, five females). Table 1 summarises the underlying malig-
nancy and corticosteroid therapy in cases. The median duration of
corticosteroid therapy prior to onset of PCP was 35 days (range
18–92), and four cases (31%) were receiving tapering doses at
diagnosis of PCP. There were no cases due to failed prophylaxis
(no case received prophylaxis prior to onset of PCP), documented
drug allergy or intolerance precluding consideration of prophy-
laxis. One case was receiving palliative care services prior to onset
of PCP symptoms. Mortality attributed to PCP was 8%.
Prophylaxis in at-risk patients
In all, 73 patients receiving corticosteroid therapy of sufficient
dose and duration were identified during the defined 6-month
period. Of these, 22 (30%) had haematological malignancy and 51
(70%) had solid tumours. Table 2 lists the frequency of diseases in
these populations. Figure 1 shows all patients who received
X25mg prednisolone or X4mg dexamethasone daily for X4
weeks, and the proportion who were also administered PCP
prophylaxis. Significantly fewer at-risk patients with solid tumours
received prophylaxis compared to patients with haematologic
malignancy (3.9 vs 63.6%, Po0.0001).
During this 6-month period, one case of PCP occurred in a
patient not receiving chemoprophylaxis. Using the number of
patients receiving corticosteroid therapy without PCP chemopro-
phylaxis as the denominator (57 patients in 6 months), the
estimated crude incidence is 18 PCP cases per 1000 patients with
malignancy receiving corticosteroid therapy for X4 weeks.
DISCUSSION
Our study focused on PCP prophylaxis in patients receiving
corticosteroid therapy for solid tumours or haematologic malig-
nancy. Although the mechanisms of immune compromise in this
population are multifactorial, corticosteroid therapy is a signifi-
cant and readily identifiable risk factor, providing opportunity for
modification of prescribing practices relevant to prophylaxis.
We have identified differences in proportion of patients with
solid tumours receiving chemoprophylaxis compared to patients
with haematologic malignancy. This may be attributed to the use
of prescriber guidelines within some groups of haematology
patients at PMCC. However, even in this group, a large proportion
(36.4%) were not prescribed chemoprophylaxis, and the observed
number of cases of PCP (seven out of 13) in haematology patients
would suggest significant under-prescribing. Our estimation of
incidence of PCP is based upon a number of assumptions,
including consistency of hospital bed-days, indications for
corticosteroid therapy, and proportion of solid and haematological
malignancy treated at PMCC during the study period. Community-
based prescription of corticosteroid therapy was not captured,
leading to possible overestimation of incidence.
In our series, predisposing corticosteroid therapy was not
administered in 11 patients with PCP. Only two cases had solid
PCP chemoprophylaxis and corticosteroid therapy
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stumours, suggesting that the vast majority of at-risk patients with
solid tumours can be identified on the basis of corticosteroid
therapy. Nine cases had haematological malignancy. Given the
heterogeneity of potential risk factors in this subgroup, distinct
recommendations for prophylaxis must be based upon the
underlying disease or predisposing chemotherapy. For example,
chemoprophylaxis should be administered for 6 months following
engraftment in allogeneic transplant recipients (Dykewicz, 2001).
This may be extended where immunosuppressive therapy or
chronic GVHD persists beyond 6 months. Chemoprophylaxis
should be considered in autologous stem cell transplant recipients
with underlying lymphoma or leukaemia, intense conditioning
regimens, or recently administered fludarabine or 2-chlorodeoxy-
adenosine (Rodriguez and Fishman, 2004). Patients receiving
alemtuzumab therapy should receive PCP chemoprophylaxis for at
least 2 months after therapy (Keating et al, 2004).
Trimethoprim–sulfamethoxazole prophylaxis
Pneumocystis jirovecii pneumonia prophylaxis is effective in
patients not infected with HIV. Munoz et al (1997) showed that
TMP–SMX (administered on weekends only) eliminated all cases
of PCP in a population of heart transplant recipients, compared to
4% incidence prior to prophylaxis. TMP–SMX has been shown to
be an effective prophylaxis in patients with cancer (Hughes et al,
1977). Daily and thrice weekly dosing regimens have demonstrated
equivalence in patients with leukaemia (Hughes et al, 1987; Rossi
et al, 1987), and twice weekly dosing has been shown to be effective
in allogeneic transplant recipients (Souza et al, 1999).
Precautions and contraindications
Contraindications to the TMP–SMX prophylaxis must be con-
sidered: documented hypersensitivity, megaloblastic anaemia due
to folate deficiency, severe renal impairment and porphyria
(Masters et al, 2003). Caution must also be exercised in patients
with impaired renal function, impaired hepatic function, severe
drug allergies, glucose-6-phosphate dehydrogenase deficiency or
blood dyscrasias. The potential for myelosuppression or drug
interactions may necessitate consideration of an alternative
prophylactic agent.
Myelosuppression has been associated with TMP–SMX use in
children with acute lymphoblastic leukaemia (Woods et al, 1984).
Conversely, in a study of adult patients with acute leukaemia, no
significant difference in myelosuppression was found when TMP–
SMX (1 double strength tablet twice daily) was compared with
placebo (Ward et al, 1993). The original reports of efficacy of
TMP–SMX for prophylaxis did not demonstrate significant
Table 1 Cases of PCP in patients receiving corticosteroid therapy, PMCC 1/1/1994–31/12/2003
Corticosteroid
a Other risk factors for PCP
Age/sex Malignancy Dose
No.
of
days Tapering Transplantation
Cytotoxic
therapy
External
beam
radiation Outcome
Solid tumours
57/M Thyroid carcinoma DXM 16mg 30 Y N Radioactive iodine N Resolved
63/M GBM DXM 16mg 34 N N N N Resolved
76/M NSCLC DXM 12mg 36 N N Gemcitabine carboplatin N Resolved
64/M SCLC DXM 16mg 28 N N Carboplatin, paclitaxel N Died
36/F Breast carcinoma PNL 25mg 40 N Autologous HSCT EC Y Resolved
65/M NSCLC DXM 16mg 88 Y N Gemcitabine Y Resolved
Haematologic malignancy
44/F NHL PNL 100mg 50 N N CHOP Y Resolved
71/M AML PNL 25mg 45 N N FLAG, hydroxyurea Y Resolved
61/F NHL DXM 16mg 35 Y N CHOP, Mabthera, RICE N Resolved
68/F NHL (cerebral metastases) DXM 8mg 92 N N CHOP, Mabthera, IT MTX, Ara-C N Resolved
18/M Burkitt’s lymphoma DXM 40mg 18 N N MTX,Ara-C Y Resolved
48/F Multiple myeloma DXM 100mg —
b Y N VAD, cyclophosphamide N Resolved
41/M Multiple myeloma DXM 16mg 25 Y Autologous HSCT PCAB, VAD, melphalan N Resolved
64/F CML PNL 25mg 33 N N IFN, hydroxyurea, busulphan,
Ara-C, idarubicin, fludarabine
N Resolved
aInitial daily dose and number of days of corticosteroid therapy prior to onset of PCP symptoms; DXM¼dexamethasone; PNL¼prednisolone.
bPatient commenced
corticosteroid therapy at another institution prior to transfer. GBM¼glioblastoma multiforme; NHL¼non-Hodgkin’s lymphoma; AML¼acute myeloid leukaemia;
CML¼chronic myeloid leukaemia; EC¼epirubicin, cyclophosphamide; CHOP¼cyclophosphamide, doxorubicin, oncovin, prednisolone; FLAG¼fludarabine, cytarabine, G-
CSF; RICE¼rituximab, ifosfamide, carboplatin, etoposide; MTX¼methotrexate; Ara-C¼cytarabine; IFN¼interferon a-2b; PCAB¼prednisolone, cyclophosphamide,
doxorubicin, carmustine; VAD¼vincristine, doxorubicin, dexamethasone; HSCT¼haematopoietic stem cell transplantation.
Table 2 At-risk patients receiving high-dose corticosteroid therapy,
PMCC 1/6/03–30/11/03
Malignancy n
Solid tumours
Lung (non-small cell) 13
Genitourinary 9
Breast 8
Gastrointestinal 7
Melanoma 4
Adenocarcinoma, unknown primary 4
Central nervous system (primary) 2
Sarcoma 2
Adenoid cystic carcinoma 1
Parotid 1
Haematologic malignancy
Multiple myeloma 14
Non-Hodgkin’s lymphoma 6
Chronic lymphocytic leukaemia 2
Total 73
PCP chemoprophylaxis and corticosteroid therapy
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smyelosuppression (Hughes et al, 1977, 1987). However, when used
for prophylaxis against bacteraemia following autologous bone
marrow transplantation, the time to neutrophil recovery is
significantly longer in patients receiving TMP–SMX, compared
to patients receiving ciprofloxacin (Imrie et al, 1995). We
recommend that an alternative prophylactic agent be used in
at-risk patients with expected myelosuppression 47 days
(Table 3).
In patients receiving chemotherapy with methotrexate, pancy-
topenia may occur if prophylactic TMP–SMX is used concur-
rently. The sulphamethoxazole component may increase toxicity of
methotrexate by displacement from binding sites or reduced renal
excretion (Masters et al, 2003; Mathew and Grossman, 2003). Small
studies of children with acute leukaemia have demonstrated both
increased free methotrexate (Ferrazzini et al, 1990) and no change
in plasma concentration of methotrexate (Beach et al, 1981) when
co-administered with TMP–SMX. In a study of patients with
rheumatoid arthritis treated with up to 25mg methotrexate per
week who received TMP–SMX prophylaxis, no patient developed
myelosuppression (Langford et al, 2003). Conversely, there are a
number of case reports of significant adverse events with the
combination (Groenendal and Rampen, 1990; Govert et al, 1992;
Steuer and Gumpel, 1998; Saravana and Lalukotta, 2003). We
therefore recommend an alternative prophylactic agent in the
setting of concurrent methotrexate therapy (Table 3).
Prophylaxis with TMP–SMX may not be tolerated in patients
with advanced malignancy and reduced oral intake due to nausea
or dysphagia. This may not have been a significant contributor
to duration of prophylaxis in our series as only one out of 13 cases
of PCP were utilising palliative care services at the time of
diagnosis. Further study is required to address the question of
appropriateness of commencing prophylaxis in the setting of
palliation.
Alternative agents
As demonstrated in HIV-infected patients (Martin et al, 1993;
Warnock and Rimland, 1996; El-Sadr et al, 1998), alternative
prophylactic agents may be used, but are associated with higher
rates of failure. Dapsone prophylaxis (50mg three times per week)
in allogeneic transplant recipients has a significantly higher
incidence of failure when compared to TMP–SMX (Souza et al,
1999). Aerosolised pentamidine (150mg every 2 weeks or 300mg
per month) used after bone marrow transplantation has been
shown to be inferior to TMP–SMX for PCP prophylaxis
(Vasconcelles et al, 2000) and associated with an increased risk
At-risk patients 
(n = 73) 
Solid tumours 
(n = 51) 
Haematological 
malignancy
(n = 22) 
No prophylaxis 
8 (36.4%) 
Prophylaxis 
14 (63.6%) 
No prophylaxis 
49 (96.1%) 
Prophylaxis 
2 (3.9%) 
Figure 1 Pneumocystis jirovecii pneumonia prophylaxis in at-risk patients receiving corticosteroid therapy, PMCC 1/6/03–30/11/03.
Table 3 Guidelines: PCP prophylaxis for patients with malignancy who receive corticosteroid therapy
Chemoprophylaxis for Pneumocystis jirovecii pneumonia should be administered when treatment with X20mg prednisolone equivalents for X1 month is planned.
First-line prophylactic agent should be trimethoprim–sulphamethoxazole (one DS
a tablet daily, one DS tablet three times weekly or two DS tablets twice weekly), unless:
(i) Myelosuppression due to chemotherapy or radiation likely to be present for 47 days
Recommend: second-line prophylactic agent
(ii) Previous allergy or hypersensitivity to sulpha-drugs
Recommend: trimethoprim–sulphamethoxazole desensitisation (unless previous anaphylaxis)
(iii) Planned methotrexate chemotherapy
Recommend: second-line prophylactic agent.
A second-line prophylactic agent should be used if trimethoprim–sulphamethoxazole is contraindicated:
(i) Dapsone (100mg daily), OR
(ii) Pentamidine
b (nebulised, 300mg monthly), OR
(iii) Atovaquone
c (1500mg daily).
Prophylaxis should continue until at least 1 month after steroid cessation. A longer period of prophylaxis may be required if ongoing chemotherapy (e.g. cytarabine,
cyclophosphamide, fludarabine, fluorouracil, methotrexate) is planned. Life-long prophylaxis should be considered if the patient has had a previous episode of PCP and
persisting immunosuppression.
aDS¼double strength; trimethoprim 160mg per 800mg sulphamethoxazole.
bScreening antibodies for T. gondii should be checked prior to use following bone marrow
transplantation.
cNo studies of efficacy in patients with malignancy.
PCP chemoprophylaxis and corticosteroid therapy
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with antibodies to Toxoplasma gondii (Machado et al, 1998). Safety
and tolerability of atovaquone prophylaxis (1500mg daily) has
been demonstrated in autologous stem cell transplant recipients
(Colby et al, 1999), but studies of efficacy in non-HIV-infected
patients are lacking. Use of clindamycin (300mg daily) and
primaquine (15mg daily) for prophylaxis in HIV-infected patients
is associated with a higher risk for developing PCP than the TMP–
SMX prophylaxis (Barber et al, 1996). Efficacy of clindamycin/
primaquine for prophylaxis in patients with malignancy has not
been reported.
Due to ease of administration and medical costs, we recommend
that dapsone be used as second-line prophylaxis if TMP–SMX is
contraindicated or not tolerated (Table 3). Nebulised pentamidine
may also be used, and atovaquone may be considered in patients
unable to tolerate TMP–SMX or dapsone.
Duration of prophylaxis
Although some have recommended that prophylaxis continue for 1
month after discontinuation of corticosteroids (Sepkowitz, 2002),
extended duration may be required with other concurrently
administered immunosuppressive therapies. For example, cytar-
abine (Hughes et al, 1975), cyclophosphamide (Kulke and Vance,
1997), methotrexate (Kane et al, 1993), fluorouracil (Hardy et al,
1987) and fludarabine (Bastion et al, 1991) have all been associated
with development of PCP in the absence of corticosteroid
treatment, although the absolute risk is unclear. We recommend
continued primary prophylaxis or lifelong secondary prophylaxis
in the setting of ongoing immunosuppression (Table 3).
Improving utilisation and prescriber practices
Suboptimal prescribing patterns for PCP chemoprophylaxis have
been described in HIV-infected patients (Montaner et al, 1996;
Schwarcz et al, 1997). Reasons are multifactorial, including patient
reluctance or inability to access healthcare services (Schwarcz et al,
1997), and failure of a treating clinician to identify the need for
prophylaxis (Auperin et al, 1994). In our patient population, it
appears that prescriber factors are a greater barrier to PCP
prophylaxis than poor access to healthcare, as no case of
noncompliance was identified in the series of PCP cases, and
patients were otherwise attending the regular review for treatment
of underlying malignancy.
We have formulated guidelines for PCP chemoprophylaxis in
patients receiving corticosteroid therapy for malignancy (Table 3).
If applied to the cases of PCP observed at PMCC, 11 out of 13 cases
(85%) could potentially have been prevented. Successful primary
prevention of PCP in this population will require a multifaceted
approach including academic detailing (one-on-one education of
clinicians and hospital pharmacists). This has previously been
successfully implemented to enhance the use of preventive
medication for corticosteroid-induced osteoporosis (Naunton
et al, 2004). Novel strategies, such as generation of computerised
clinical reminders (Kralj et al, 2003) from pharmacy records of
dispensed corticosteroid, should also be considered.
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